Department of Epidemiology, Geisel School of Medicine, Dartmouth College, Lebanon, New Hampshire.
Department of Neurological Surgery, University of California San Francisco, San Francisco, California.
Cancer Epidemiol Biomarkers Prev. 2023 Oct 2;32(10):1328-1337. doi: 10.1158/1055-9965.EPI-23-0331.
Immune profiles have been associated with bladder cancer outcomes and may have clinical applications for prognosis. However, associations of detailed immune cell subtypes with patient outcomes remain underexplored and may contribute crucial prognostic information for better managing bladder cancer recurrence and survival.
Bladder cancer case peripheral blood DNA methylation was measured using the Illumina HumanMethylationEPIC array. Extended cell-type deconvolution quantified 12 immune cell-type proportions, including memory, naïve T and B cells, and granulocyte subtypes. DNA methylation clocks determined biological age. Cox proportional hazards models tested associations of immune cell profiles and age acceleration with bladder cancer outcomes. The partDSA algorithm discriminated 10-year overall survival groups from clinical variables and immune cell profiles, and a semi-supervised recursively partitioned mixture model (SS-RPMM) with DNA methylation data was applied to identify a classifier for 10-year overall survival.
Higher CD8T memory cell proportions were associated with better overall survival [HR = 0.95, 95% confidence interval (CI) = 0.93-0.98], while higher neutrophil-to-lymphocyte ratio (HR = 1.36, 95% CI = 1.23-1.50), CD8T naïve (HR = 1.21, 95% CI = 1.04-1.41), neutrophil (HR = 1.04, 95% CI = 1.03-1.06) proportions, and age acceleration (HR = 1.06, 95% CI = 1.03-1.08) were associated with worse overall survival in patient with bladder cancer. partDSA and SS-RPMM classified five groups of subjects with significant differences in overall survival.
We identified associations between immune cell subtypes and age acceleration with bladder cancer outcomes.
The findings of this study suggest that bladder cancer outcomes are associated with specific methylation-derived immune cell-type proportions and age acceleration, and these factors could be potential prognostic biomarkers.
免疫特征与膀胱癌结局相关,并且可能在预后方面具有临床应用价值。然而,详细的免疫细胞亚型与患者结局的关联仍未得到充分探索,并且可能为更好地管理膀胱癌复发和生存提供关键的预后信息。
使用 Illumina HumanMethylationEPIC 阵列测量膀胱癌病例外周血 DNA 甲基化。扩展的细胞类型去卷积量化了 12 种免疫细胞类型的比例,包括记忆 T 和 B 细胞以及粒细胞亚型。DNA 甲基化时钟确定了生物年龄。Cox 比例风险模型测试了免疫细胞特征和年龄加速与膀胱癌结局的关联。partDSA 算法从临床变量和免疫细胞特征中区分了 10 年总生存率组,并且应用半监督递归分区混合模型 (SS-RPMM) 与 DNA 甲基化数据一起识别了 10 年总生存率的分类器。
较高的 CD8T 记忆 T 细胞比例与更好的总生存率相关 [HR = 0.95,95%置信区间 (CI) = 0.93-0.98],而较高的中性粒细胞与淋巴细胞比值 (HR = 1.36,95% CI = 1.23-1.50)、CD8T 幼稚细胞 (HR = 1.21,95% CI = 1.04-1.41)、中性粒细胞 (HR = 1.04,95% CI = 1.03-1.06) 比例和年龄加速 (HR = 1.06,95% CI = 1.03-1.08) 与膀胱癌患者的总生存率较差相关。partDSA 和 SS-RPMM 将受试者分为五个具有显著总生存率差异的组。
我们确定了免疫细胞亚型和年龄加速与膀胱癌结局之间的关联。
本研究的结果表明,膀胱癌结局与特定的基于甲基化的免疫细胞类型比例和年龄加速相关,这些因素可能是潜在的预后生物标志物。